[{"indications": "Indications\u00a0\n(From Topical retinoids and related preparations for acne: British National Formulary)\nTopical retinoids and related preparations for acne; oral treatment\r\n(\n(From 13.6.2 Oral preparations for acne: British National Formulary)\n13.6.2 Oral preparations for acne)", "name": "ISOTRETINOIN With antibacterial", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.6 Acne and rosacea", "13.6.1 Topical preparations for acne", "Topical retinoids and related preparations for acne", "ISOTRETINOIN", "With antibacterial"], "cautions": "Cautions\u00a0(topical application only) \n(From Topical retinoids and related preparations for acne: British National Formulary)\nTopical retinoids and related preparations for acne;\r\nalso personal or familial history of non-melanoma skin\r\ncancer", "side-effects": "Side-effects\u00a0(topical application only) \n(From Topical retinoids and related preparations for acne: British National Formulary)\nSide-effects\u00a0Local reactions include burning, erythema, stinging, pruritus, dry or peeling skin (discontinue if severe). Increased sensitivity to UVB light or sunlight occurs. Temporary changes of skin pigmentation with tretinoin have been reported. Eye irritation and oedema, and blistering or crusting of skin have been reported rarely.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/61338.htm", "doses": ["Apply thinly 1\u20132 times daily", "Name[Isotrexin\u00ae (Stiefel) ] Gel, isotretinoin  0.05%, erythromycin 2% in ethanolic\r\nbasis, net price 30\u00a0g = \u00a37.47. \r\n    Label:\r\n    11Excipients  include butylated hydroxytoluene"], "pregnancy": "Pregnancy\u00a0(topical application only) \n(From Topical retinoids and related preparations for acne: British National Formulary)\nPregnancy\u00a0Topical retinoids are contra-indicated in pregnancy; women of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered effective)."}, {"indications": "Indications\u00a0\n(From Topical retinoids and related preparations for acne: British National Formulary)\nTopical retinoids and related preparations for acne; oral treatment\r\n(\n(From 13.6.2 Oral preparations for acne: British National Formulary)\n13.6.2 Oral preparations for acne)", "name": "ISOTRETINOIN - TOPICAL RETINOIDS AND RELATED PREPARATIONS FOR ACNE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.6 Acne and rosacea", "13.6.1 Topical preparations for acne", "Topical retinoids and related preparations for acne", "ISOTRETINOIN"], "cautions": "Cautions\u00a0(topical application only) \n(From Topical retinoids and related preparations for acne: British National Formulary)\nTopical retinoids and related preparations for acne;\r\nalso personal or familial history of non-melanoma skin\r\ncancer", "side-effects": "Side-effects\u00a0(topical application only) \n(From Topical retinoids and related preparations for acne: British National Formulary)\nSide-effects\u00a0Local reactions include burning, erythema, stinging, pruritus, dry or peeling skin (discontinue if severe). Increased sensitivity to UVB light or sunlight occurs. Temporary changes of skin pigmentation with tretinoin have been reported. Eye irritation and oedema, and blistering or crusting of skin have been reported rarely.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/61336.htm", "doses": ["Apply thinly 1\u20132 times daily"], "pregnancy": "Pregnancy\u00a0(topical application only) \n(From Topical retinoids and related preparations for acne: British National Formulary)\nPregnancy\u00a0Topical retinoids are contra-indicated in pregnancy; women of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered effective)."}, {"indications": "Indications\u00a0\n(From Topical retinoids and related preparations for acne: British National Formulary)\nTopical retinoids and related preparations for acne; oral treatment\r\n(\n(From 13.6.2 Oral preparations for acne: British National Formulary)\n13.6.2 Oral preparations for acne)", "name": "ISOTRETINOIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.6 Acne and rosacea", "13.6.1 Topical preparations for acne", "Topical retinoids and related preparations for acne", "ISOTRETINOIN"], "cautions": "Cautions\u00a0(topical application only) \n(From Topical retinoids and related preparations for acne: British National Formulary)\nTopical retinoids and related preparations for acne;\r\nalso personal or familial history of non-melanoma skin\r\ncancer", "side-effects": "Side-effects\u00a0(topical application only) \n(From Topical retinoids and related preparations for acne: British National Formulary)\nSide-effects\u00a0Local reactions include burning, erythema, stinging, pruritus, dry or peeling skin (discontinue if severe). Increased sensitivity to UVB light or sunlight occurs. Temporary changes of skin pigmentation with tretinoin have been reported. Eye irritation and oedema, and blistering or crusting of skin have been reported rarely.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/61336.htm", "doses": ["Apply thinly 1\u20132 times daily"], "pregnancy": "Pregnancy\u00a0(topical application only) \n(From Topical retinoids and related preparations for acne: British National Formulary)\nPregnancy\u00a0Topical retinoids are contra-indicated in pregnancy; women of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered effective)."}, {"indications": "Indications\u00a0\n(From Oral retinoid for acne: British National Formulary)\nOral retinoid for acne", "name": "ISOTRETINOIN - ORAL RETINOID FOR ACNE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.6 Acne and rosacea", "13.6.2 Oral preparations for acne", "Oral retinoid for acne", "ISOTRETINOIN"], "cautions": "Cautions\u00a0\n(From Oral retinoid for acne: British National Formulary)\nOral retinoid for acne; also avoid blood donation during treatment and for at least 1 month after\r\ntreatment; history of depression; monitor all patients for depression; measure hepatic function and serum lipids before treatment, 1 month\r\nafter starting and then every 3 months (reduce dose or discontinue\r\nif transaminase or serum lipids persistently raised); discontinue if uncontrolled hypertriglyceridaemia or pancreatitis; diabetes; dry eye syndrome (associated with risk of keratitis); avoid keratolytics; interactions: Appendix 1 (retinoids)Pregnancy prevention\u00a0In women of child-bearing potential, exclude pregnancy up to 3 days\r\nbefore treatment (start treatment on day 2 or 3 of menstrual cycle),\r\nevery month during treatment (unless there are compelling reasons\r\nto indicate that there is no risk of pregnancy), and 5 weeks after\r\nstopping treatment\u2014perform pregnancy test in the first 3 days of the\r\nmenstrual cycle. Women must practise effective contraception\r\nfor at least 1 month before starting treatment, during treatment,\r\nand for at least 1 month after stopping treatment. Women\r\nshould be advised to use at least 1 method of contraception, but ideally\r\nthey should use 2 methods of contraception. Oral progestogen-only\r\ncontraceptives are not considered effective. Barrier methods should\r\nnot be used alone, but can be used in conjunction with other contraceptive\r\nmethods. Each prescription for isotretinoin should be limited to a\r\nsupply of up to 30 days\u2019 treatment and dispensed within 7 days of\r\nthe date stated on the prescription. Women should be advised to discontinue\r\ntreatment and to seek prompt medical attention if they become pregnant\r\nduring treatment or within 1 month of stopping treatment.Counselling\u00a0Warn patient to avoid\r\nwax epilation (risk of epidermal stripping), dermabrasion, and laser\r\nskin treatments (risk of scarring) during treatment and for at least\r\n6 months after stopping; patient should\r\navoid exposure to UV light (including sunlight) and use sunscreen\r\nand emollient (including lip balm) preparations from the start of\r\ntreatment.", "side-effects": "Side-effects\u00a0dryness of skin (with dermatitis, scaling, thinning,\r\nerythema, pruritus), epidermal fragility (trauma may cause blistering),\r\ndryness of lips (sometimes cheilitis), dryness of eyes (with blepharitis\r\nand conjunctivitis), dryness of pharyngeal mucosa (with hoarseness),\r\ndryness of nasal mucosa (with epistaxis), headache, myalgia and arthralgia,\r\nraised plasma-triglyceride concentration (risk of pancreatitis if\r\ntriglycerides above 9\u00a0mmol/litre), raised serum-cholesterol concentration\r\n(with reduced high-density lipoprotein concentration), raised blood-glucose\r\nconcentration, raised serum-transaminase concentration, haematuria\r\nand proteinuria, thrombocytopenia, thrombocytosis, neutropenia and\r\nanaemia; rarely mood changes (depression, aggressive\r\nbehaviour, anxiety, and very rarely psychosis and suicidal ideation)\u2014expert\r\nreferral required, skin reactions (including reports of Stevens-Johnson\r\nsyndrome and toxic epidermal necrolysis), alopecia; very rarely nausea, hepatitis, inflammatory bowel disease, gastro-intestinal\r\nhaemorrhage, haemorrhagic diarrhoea (discontinue treatment), benign\r\nintracranial hypertension (avoid concomitant tetracyclines), convulsions,\r\nmalaise, drowsiness, dizziness, diabetes mellitus, lymphadenopathy,\r\nhyperuricaemia, glomerulonephritis, tendinitis, arthritis, raised\r\nserum-creatine kinase concentration, bone changes (including reduced\r\nbone density, early epiphyseal closure, and skeletal hyperostosis)\r\nand calcification of tendons and ligaments following long-term administration,\r\nvisual disturbances (papilloedema, corneal opacities, cataracts, decreased\r\nnight vision, photophobia, blurred vision, colour blindness)\u2014expert\r\nreferral required and consider withdrawal, decreased tolerance to\r\ncontact lenses, keratitis, impaired hearing, Gram-positive infections\r\nof skin and mucous membranes, exacerbation of acne, acne fulminans,\r\nallergic vasculitis and granulomatous lesions, paronychia, hirsutism,\r\nnail dystrophy, skin hyperpigmentation, photosensitivity, increased\r\nsweating", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106181.htm", "doses": ["adult and child over 12 years, 500\u00a0micrograms/kg daily (in\r\n1\u20132 divided doses), increased if necessary to 1\u00a0mg/kg daily, for 16\u201324\r\nweeks (repeat treatment course after a period of at least 8 weeks\r\nif relapse after first course); max. cumulative dose 150\u00a0mg/kg per\r\ncourse"], "pregnancy": "Pregnancy\u00a0avoid\u2014teratogenic; effective contraception must be\r\nused\u2014see Pregnancy Prevention above"}]